Eribulin for Hemangiosarcoma and Epithelioid Hemangioendothelioma

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Gregory Cote, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Massachusetts General Hospital

No Placebo Group

Prior Safety Data

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

Eligibility Criteria

This trial is for adults over 18 with advanced angiosarcoma or epithelioid hemangioendothelioma (EHE) who've had at least one prior treatment. They must have measurable disease, a life expectancy over three months, and normal organ/marrow function. Women of childbearing age and men must use contraception. Those with brain metastases, certain heart conditions, or uncontrolled illnesses can't join.

Inclusion Criteria

You are expected to live for at least 3 more months.

My cancer has worsened after treatment or during a no-treatment phase in the last 3 months.

Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation, and 4 months after completion of Eribulin administration. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of Eribulin administration

Exclusion Criteria

I am not pregnant or breastfeeding.

I haven't had chemotherapy, radiotherapy, or targeted therapies recently and have recovered from any serious side effects.

I have brain metastases or leptomeningeal disease.

Participant Groups

The study tests Eribulin as a potential treatment for Angiosarcoma or Epithelioid Hemangioendothelioma (EHE). Participants will receive Eribulin after having progressed on previous therapies. The trial includes tumor biopsies before and during treatment to assess the drug's effect.

Group I: Eribulin Experimental Treatment 1 Intervention

* Eribulin administered twice per cycle intravenously * Each cycle contains 21 days * Dosing is per the FDA label for other cancers

Eribulin is already approved in European Union, United States, Japan, Canada for the following indications:

🇪🇺 Approved in European Union as Halaven for:

• Locally advanced or metastatic breast cancer

🇺🇸 Approved in United States as Halaven for:

• Metastatic breast cancer
• Liposarcoma

🇯🇵 Approved in Japan as Halaven for:

• Breast cancer
• Soft tissue sarcoma

🇨🇦 Approved in Canada as Halaven for:

• Metastatic breast cancer

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Dana Farber Cancer Institute Boston, MA

Massachusetts General Hospital Boston, MA

Who Is Running the Clinical Trial?

Massachusetts General Hospital Lead Sponsor

Eisai Inc. Industry Sponsor

References